1379342-51-4

Usage

Uses

Used in Pharmaceutical Industry:
3-bromo-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol is used as a reagent for the preparation of oral p300/CBP histone acetyltransferase inhibitors. These inhibitors play a crucial role in cancer therapy, as they target specific enzymes involved in the regulation of gene expression, thereby affecting the growth and progression of cancer cells.
In Cancer Therapy:
3-bromo-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol is used as a key component in the development of histone acetyltransferase inhibitors for cancer treatment. These inhibitors help modulate the activity of p300/CBP enzymes, which are known to be involved in the regulation of gene expression and are often dysregulated in cancer cells. By targeting these enzymes, the compound can potentially contribute to the suppression of tumor growth and the improvement of cancer treatment outcomes.

Upstream product

• 1336955-89-5 3-bromo-5,6-dihydro-7H-cyclopenta[b]pyridin-7-one 
• 158331-18-1 3-bromo-6,7-dihydro-5H-cyclopenta[b]pyridine 
• 533-37-9 2,3-cyclopentenopyridine 
• 7148-07-4 1-pyrrolidinocyclopent-1-ene 

Downstream Products

• 1336955-89-5 3-bromo-5,6-dihydro-7H-cyclopenta[b]pyridin-7-one 

Relevant academic research and scientific papers

HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF

The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS

Provided are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt, thereof for use in methods of treatment heart diseases through cardiac sarcomere inhibtion.

FACTOR XIA INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

ANTIDIABETIC BICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-co

NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A1, A2 and n are as described herein, compositions including the compounds and methods of using the compounds.

NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES

The invention provides novel compounds having the general Formula (I), wherein R1, R2, R3, R4 R5, R6, R7, R8 R9, R10, R11, R12, A1, A2 and n are as described herein, compositions including the compounds and methods of using the compounds.